PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33307872-6 2021 Sunitinib and regorafenib are inhibitors of multiple tyrosine kinases, including KIT, PDGFRalpha, PDGFRbeta, and VEGFRs, and are approved for the management of imatinib- and imatinib/sunitinib-refractory GIST patients, respectively. regorafenib 14-25 platelet derived growth factor receptor beta Homo sapiens 98-107 30069758-1 2018 Regorafenib (BAY 73-4506, Stivarga ) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-beta, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF). regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 135-145 32207565-1 2020 BACKGROUND: Regorafenib is a small molecule multikinase inhibitor that inhibits multiple kinases including BRAF, KIT, PDGFRB, RAF, RET, and VEGFR1-3. regorafenib 12-23 platelet derived growth factor receptor beta Homo sapiens 118-124 32052681-7 2021 A marked reduction in the expression of VEGFR, PDGFR, EGFR and the downstream target, ERK, was observed with Regorafenib treatment alone or in combination with radiation. regorafenib 109-120 platelet derived growth factor receptor beta Homo sapiens 47-52 29359239-3 2018 Regorafenib is a potent inhibitor of angiogenic (VEGFR 1-3, PDGFR-b) as well as oncogenic (c-KIT, RET, FGFR, Raf) kinases. regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 60-67 31608707-12 2020 Regorafenib is a multikinase inhibitor targeting BRAF, VEGFR-1/2/3, KIT, TIE-2, PDGFR-beta, fibroblast growth factor receptor 1 (FGFR-1), RET, RAF-1, and p38 MAP kinase. regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 80-90 30069758-1 2018 Regorafenib (BAY 73-4506, Stivarga ) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-beta, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF). regorafenib 13-24 platelet derived growth factor receptor beta Homo sapiens 135-145 26865419-4 2016 A novel oral multikinase inhibitor regorafenib inhibits receptor tyrosine kinases expressed on stromal cells (vascular endothelial growth factor receptor 1-3, TIE2, PDGFR-beta, and fibroblast growth factors) and tumor cells (c-KIT, RET, and BRAF). regorafenib 35-46 platelet derived growth factor receptor beta Homo sapiens 165-175 25336117-0 2015 A novel germline mutation of PDGFR-beta might be associated with clinical response of colorectal cancer to regorafenib. regorafenib 107-118 platelet derived growth factor receptor beta Homo sapiens 29-39 26651387-3 2016 AREAS COVERED: Regorafenib, an oral multitargeted inhibitor with activity against multiple kinases including KIT, RET, RAF1, BRAF, angiogenesis (VEGFR, TIE-2) and those involved in tumor microenvironment (PDGFR and FGFR) was introduced after the successful Phase III GRID (GIST - Regorafenib In progressive Disease) clinical trial. regorafenib 15-26 platelet derived growth factor receptor beta Homo sapiens 205-210 27045179-1 2016 Regorafenib {systematic name: 4-[4-({[4-chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide}, C21H15ClF4N4O3, is a potent anticancer and anti-angiogenic agent that possesses various activities on the VEGFR, PDGFR, raf and/or flt-3 kinase signaling molecules. regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 252-257 22614970-2 2012 Regorafenib is a structurally unique inhibitor of multiple cancer-associated kinases, including KIT and platelet-derived growth factor receptor (PDGFR), with broad-spectrum anticancer activity in preclinical and early-phase trials. regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 104-143 23435872-5 2013 In this scenario, regorafenib has emerged as a novel, orally active, multitarget compound with potent activity against a number of angiogenic and stromal TKs, including vascular endothelial growth factor receptor 2 (VEGFR-2), tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE-2), fibroblast growth factor receptor 1 (FGFR-1), and platelet-derived growth factor receptor (PDGFR). regorafenib 18-29 platelet derived growth factor receptor beta Homo sapiens 349-388 23435872-5 2013 In this scenario, regorafenib has emerged as a novel, orally active, multitarget compound with potent activity against a number of angiogenic and stromal TKs, including vascular endothelial growth factor receptor 2 (VEGFR-2), tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE-2), fibroblast growth factor receptor 1 (FGFR-1), and platelet-derived growth factor receptor (PDGFR). regorafenib 18-29 platelet derived growth factor receptor beta Homo sapiens 390-395 24559322-1 2014 Regorafenib is an oral multikinase inhibitor that blocks the activity of protein kinases involved in the regulation of tumor angiogenesis (VEGFR1, 2, 3; angiopoietin-1 receptor), oncogenesis (stem cell growth factor receptor; RET; BRAF including BRAFV600E), and tumor microenvironment (PDGFR-beta and FGFR). regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 286-296 24756792-1 2014 Regorafenib (BAY 73-4506, Stivarga ) is an oral diphenylurea multikinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-beta, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF). regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 134-144 22614970-2 2012 Regorafenib is a structurally unique inhibitor of multiple cancer-associated kinases, including KIT and platelet-derived growth factor receptor (PDGFR), with broad-spectrum anticancer activity in preclinical and early-phase trials. regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 145-150 34706060-2 2022 Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor beta (PDGFR-beta), and fibroblast growth factor receptors (FGFRs). regorafenib 0-11 platelet derived growth factor receptor beta Homo sapiens 76-120 22577890-1 2012 INTRODUCTION: Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-beta, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. regorafenib 14-25 platelet derived growth factor receptor beta Homo sapiens 129-139 22577890-1 2012 INTRODUCTION: Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-beta, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. regorafenib 27-38 platelet derived growth factor receptor beta Homo sapiens 129-139 22421192-1 2012 PURPOSE: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-beta, FGFR), and oncogenic kinases (KIT, RET, and RAF). regorafenib 9-20 platelet derived growth factor receptor beta Homo sapiens 100-110 21170960-4 2011 Furthermore, regorafenib inhibits additional angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-beta and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF. regorafenib 13-24 platelet derived growth factor receptor beta Homo sapiens 65-119